ASP3652

small molecule FAAH inhibitor

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

1.	Interstitial Cystitis (Interstitial Cystitis, Chronic) 06/01/2021 - "An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions." 06/01/2021 - "The primary purpose of this study was to evaluate the effect of the fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on efficacy and safety in patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). "
2.	Pelvic Pain 01/01/2020 - "ASP3652 is a peripherally acting FAAH inhibitor in development for the treatment of chronic bladder and pelvic pain disorders. " 05/01/2017 - "To examine the effect of a peripherally active fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on safety and efficacy outcomes in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). "
3.	Prostatitis 05/01/2017 - "To examine the effect of a peripherally active fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on safety and efficacy outcomes in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). "

1.	fatty-acid amide hydrolase (fatty acid amide hydrolase)